IRF8 has previously been described to function as a tumor suppressor in multiple cancer types [12,13], including chronic myeloid leukemia (CML) [14,15,16,17] and murine acute promyelocytic leukemia (APL), a subclass of AML [18,19]. This evidence concerns the gene IRF8 and chronic myelogenous leukemia, BCR-ABL1 positive.